ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
The Stifel Nicolaus Healthcare Conferenceon Wednesday, September 5, 2012, at 3:50 p.m. Eastern Timeat the Four Seasons Hotelin Boston.
The Rodman & Renshaw Annual
Global Investment Conferenceon Tuesday, September 11, 2012, at 3:15 p.m. Eastern Timeat The Waldorf= Astoria Hotelin New York City.
Live webcasts of these presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for two weeks following the applicable presentation.
ACADIA is a biopharmaceutical company focused on innovative treatments
that address unmet medical needs in neurological and related central
nervous system disorders. ACADIA has a pipeline of product candidates
led by pimavanserin, which is in Phase III development as a potential
first-in-class treatment for Parkinson's disease psychosis. ACADIA also
has clinical-stage programs for chronic pain and glaucoma in
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, either alone or with a partner,
including clinical trials, and the benefits to be derived from ACADIA’s
product candidates, in each case including pimavanserin. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that
past results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2011
as well as ACADIA’s subsequent filings with the
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer